ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 876,36
1,10%
Dow Jones
41 989,96
-0,03%
DAX
22 539,98
1,71%
Brent Oil
74,365
-0,07%
Bitcoin
84 952,69
-0,26%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. BioMarin Pharmaceutical Inc (BMRN) Cours

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc (BMRN)

NASDAQ
67,94
-2,75
(-3,89%)
Fermé 02 Avril 10:00PM
Retardé de 15 minutes
67,20
-0,74
(-1,09%)
Après les heures de négociation: 1:59AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
67,20
Prix Achat
65,00
Prix Vente
69,98
Volume échangé
1 297 818
67,835 Fourchette du Jour 70,6271
60,63 Plage de 52 semaines 94,85
Cap du marché
12,82B
Clôture Veille
70,69
Ouverture
70,36
Dernière Transaction
4900
@
67.2
(formt)
Dernière heure de transaction
Volume financier
US$ 89 612 307
VWAP
69,0484
Volume moyen (3 m)
1 573 201
Actions en circulation
190 777 052
Rendement du Dividende
-
Ratio Cours sur Bénéfices
30,36
Bénéfice par action (BPA)
2,24
Chiffre d'affairess
2,85B
Bénéfice net
426,86M

À propos de BioMarin Pharmaceutical Inc

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition ... BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.biomarin.com
Siège social
Wilmington, Delaware, USA
Fondé
-
BioMarin Pharmaceutical Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker BMRN. Le dernier cours de clôture d'BioMarin Pharmaceutical était de US$70,69. Au cours de la dernière année, les actions de BioMarin Pharmaceutical ont été négociées dans une fourchette de prix de US$ 60,63 à US$ 94,85.

BioMarin Pharmaceutical compte actuellement 190 777 052 actions en circulation. La capitalisation boursière d'BioMarin Pharmaceutical est de US$13,49 milliard. BioMarin Pharmaceutical a un ratio cours/bénéfice (ratio PE) de 30.36.

Flux d'options BioMarin Pharmaceutical (BMRN)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

33k

Calls / Puts

100,00%

Ach. / Vent.

0,00%

OTM / ITM

100,00%

Sweeps Ratio

0,00%

BMRN Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
21 Mars 2025
BMRN (-3,89%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
19 Mars 2025
BMRN (-3,89%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
19 Mars 2025
BMRN (-3,89%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
19 Mars 2025
BMRN (-3,89%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Mars 2025
BMRN (-3,89%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Mars 2025
BMRN (-3,89%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Mars 2025
BMRN (-3,89%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Mars 2025
BMRN (-3,89%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Mars 2025
BMRN (-3,89%)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-4.93-6.8348814640272.1373.1867.2142810471.56183379CS
4-3.72-5.2453468697170.9273.5167.2145446071.29927967CS
120.130.19382734456567.0773.5160.63157320167.1929701CS
26-3.46-4.8966883668370.6673.5160.63148526266.97173192CS
52-19.78-22.740859967886.9894.8560.63183689676.17359653CS
156-9.98-12.93081109177.18117.7760.63150548985.02766022CS
260-14.8-18.048780487882131.94560.63147315285.09081964CS

BMRN - Frequently Asked Questions (FAQ)

What is the current BioMarin Pharmaceutical share price?
The current share price of BioMarin Pharmaceutical is US$ 67,20
How many BioMarin Pharmaceutical shares are in issue?
BioMarin Pharmaceutical has 190 777 052 shares in issue
What is the market cap of BioMarin Pharmaceutical?
The market capitalisation of BioMarin Pharmaceutical is USD 13,49B
What is the 1 year trading range for BioMarin Pharmaceutical share price?
BioMarin Pharmaceutical has traded in the range of US$ 60,63 to US$ 94,85 during the past year
What is the PE ratio of BioMarin Pharmaceutical?
The price to earnings ratio of BioMarin Pharmaceutical is 30,36
What is the cash to sales ratio of BioMarin Pharmaceutical?
The cash to sales ratio of BioMarin Pharmaceutical is 4,54
What is the reporting currency for BioMarin Pharmaceutical?
BioMarin Pharmaceutical reports financial results in USD
What is the latest annual turnover for BioMarin Pharmaceutical?
The latest annual turnover of BioMarin Pharmaceutical is USD 2,85B
What is the latest annual profit for BioMarin Pharmaceutical?
The latest annual profit of BioMarin Pharmaceutical is USD 426,86M
What is the registered address of BioMarin Pharmaceutical?
The registered address for BioMarin Pharmaceutical is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the BioMarin Pharmaceutical website address?
The website address for BioMarin Pharmaceutical is www.biomarin.com
Which industry sector does BioMarin Pharmaceutical operate in?
BioMarin Pharmaceutical operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
RSLSReShape Lifesciences Inc
US$ 1,61
(346,60%)
255,08M
BIAFbioAffinity Technologies Inc
US$ 1,10
(323,08%)
497,52M
ICCTiCoreConnect Inc
US$ 4,65
(107,59%)
209,7M
GATEMarblegate Acquisition Corporation
US$ 36,05
(83,83%)
159,59k
QSGQuantaSing Group Ltd
US$ 6,55
(62,94%)
10,27M
GDHGGolden Heaven Group Holdings Ltd
US$ 0,560899
(-88,09%)
16,12M
TBHBrag House Holdings Inc
US$ 1,2601
(-80,94%)
4,76M
LPROOpen Lending Corporation
US$ 1,16
(-57,97%)
21,52M
CMBMCambium Networks Corporation
US$ 0,3122
(-55,75%)
2,3M
APTOAptose Biosciences Inc
US$ 1,61
(-48,89%)
670,38k
BIAFbioAffinity Technologies Inc
US$ 1,10
(323,08%)
497,52M
DMNDamon Inc
US$ 0,0116
(-15,94%)
399,03M
STSSSharps Technology Inc
US$ 0,0273
(-8,70%)
348M
RSLSReShape Lifesciences Inc
US$ 1,61
(346,60%)
255,08M
NVDANVIDIA Corporation
US$ 110,15
(1,63%)
222,61M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
BMRN
BioMarin Pharmaceutical
USOTC
TXTM
ProText Mobility (PK)
OKEX
MANAUSDT
Decentraland
GATE
UMXETH
UniMex Network
DGFX
DIYUSDT
DIYChain Token
BOV
INNT3
INTER CONSTRUTORA ON
GATE
AMPETH
Amp
NASDAQ
CADL
Candel Therapeutics
HUOB
ACHETH
Alchemy
BIT
SFT
Softlab
FTSE
E1010
FTSEurofirst 300 Technol...
KRKN
SBRUSD
Saber Protocol Token
COIN
ICOLEUR
Icolcoin
KUCN
LABTC
LAToken
BIT
FARMAA
H Farm
SUSHI
BANKETH
Bankless Token
Delayed Upgrade Clock
ADVFN Logo
France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces